Stifel analyst Alex Thompson raised the firm’s price target on Immunovant (IMVT) to $61 from $58 and keeps a Buy rating on the shares following ...

Immunovant (IMVT) reported best absolute improvements with IMVT-1402 in myasthenia gravis and chronic inflammatory demyelinating polyneuropathy, and while H.C. Wainwright analyst Douglas Tsao was ...

Immunovant (NASDAQ:IMVT – Get Free Report)‘s stock had its “buy” rating restated by equities researchers at HC Wainwright in ...

Immunovant's batoclimab shows strong efficacy in MG & CIDP, but shifts focus to the lead drug IMVT-1402 for these indications to induce deeper, lasting relief.

For more on Immunovant’s new data, go here; for more on Sarepta’s gene therapy, go here; to learn more about Zealand’s deal with Roche, go here; and to read about the panels at our Breakthrough East ...

AstraZeneca signed a deal with Alteogen worth up to $1.35 billion for subcutaneous cancer drugs. Taiho Pharmacetical bought ...

Andrew Baum, Pfizer's chief strategy and innovation officer, talked Thursday about the pharmaceutical company's drug ...

To Novartis, fresh late-stage data support the idea that its intrathecal drug, which has the same active ingredient as ...

Shares of ARS Pharmaceuticals bounded off their 50-day line Thursday after the biotech company reported an unexpected ...